Raymond James & Associates Buys 74,829 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Raymond James & Associates boosted its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 29.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 326,295 shares of the medical equipment provider’s stock after acquiring an additional 74,829 shares during the period. Raymond James & Associates’ holdings in Intuitive Surgical were worth $130,221,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in ISRG. Arthur M. Cohen & Associates LLC lifted its position in Intuitive Surgical by 3.9% during the first quarter. Arthur M. Cohen & Associates LLC now owns 9,195 shares of the medical equipment provider’s stock valued at $3,670,000 after buying an additional 345 shares during the period. Maryland State Retirement & Pension System lifted its position in Intuitive Surgical by 0.9% during the first quarter. Maryland State Retirement & Pension System now owns 27,423 shares of the medical equipment provider’s stock valued at $10,209,000 after buying an additional 233 shares during the period. Teamwork Financial Advisors LLC lifted its position in Intuitive Surgical by 32.1% during the first quarter. Teamwork Financial Advisors LLC now owns 25,930 shares of the medical equipment provider’s stock valued at $10,348,000 after buying an additional 6,299 shares during the period. Veracity Capital LLC purchased a new position in Intuitive Surgical during the first quarter valued at $243,000. Finally, American National Bank & Trust Co. VA purchased a new position in Intuitive Surgical during the first quarter valued at $937,000. Institutional investors own 83.64% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on ISRG shares. BTIG Research lifted their price target on Intuitive Surgical from $412.00 to $421.00 and gave the stock a “buy” rating in a research report on Friday, April 19th. Raymond James lifted their price target on Intuitive Surgical from $372.00 to $435.00 and gave the stock an “outperform” rating in a research report on Thursday, January 25th. Royal Bank of Canada lifted their price target on Intuitive Surgical from $400.00 to $432.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 24th. Wells Fargo & Company lifted their price target on Intuitive Surgical from $363.00 to $416.00 and gave the stock an “overweight” rating in a research report on Friday, January 19th. Finally, StockNews.com lowered Intuitive Surgical from a “buy” rating to a “hold” rating in a research report on Thursday, February 29th. Five analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $396.17.

Intuitive Surgical Price Performance

Shares of NASDAQ ISRG traded down $3.52 during midday trading on Tuesday, reaching $370.62. 1,212,524 shares of the stock traded hands, compared to its average volume of 1,644,877. The stock has a market capitalization of $131.46 billion, a PE ratio of 66.90, a P/E/G ratio of 4.85 and a beta of 1.36. Intuitive Surgical, Inc. has a one year low of $254.85 and a one year high of $403.76. The company’s 50 day moving average is $385.96 and its 200 day moving average is $348.19.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.10. The firm had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.87 billion. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The company’s quarterly revenue was up 11.5% compared to the same quarter last year. During the same period in the prior year, the company earned $1.00 EPS. As a group, equities analysts forecast that Intuitive Surgical, Inc. will post 4.8 EPS for the current year.

Insider Buying and Selling

In related news, Director Alan J. Levy sold 2,000 shares of the firm’s stock in a transaction on Tuesday, April 23rd. The stock was sold at an average price of $370.70, for a total value of $741,400.00. Following the completion of the sale, the director now directly owns 25,319 shares in the company, valued at $9,385,753.30. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other news, EVP Robert Desantis sold 376 shares of Intuitive Surgical stock in a transaction on Monday, April 29th. The stock was sold at an average price of $375.39, for a total transaction of $141,146.64. Following the completion of the sale, the executive vice president now directly owns 5,507 shares in the company, valued at $2,067,272.73. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Alan J. Levy sold 2,000 shares of the firm’s stock in a transaction on Tuesday, April 23rd. The shares were sold at an average price of $370.70, for a total value of $741,400.00. Following the transaction, the director now owns 25,319 shares in the company, valued at approximately $9,385,753.30. The disclosure for this sale can be found here. Insiders sold a total of 226,967 shares of company stock worth $87,848,586 over the last three months. 0.80% of the stock is owned by insiders.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.